ImmuCell Corporation (NASDAQ:ICCC) Q1 2026 Earnings Call Transcript
Operator: Good morning, and welcome to the ImmuCell Corporation conference call to discuss unaudited first quarter 2026 financial results.
Immucell Corp (ICCC)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 151,789 | $960,824 | +1% | 0% |
| 2. | Citadel Investment Group Ken Griffin | 35,696 | $225,956 | -10% | 0% |
| 3. | Bailard Inc Thomas Bailard | 10,102 | $63,946 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.50 | 2,432 | $13,376.49 | 9,738 | 2025-12-04 | Filing | |
| $5.05 | 3,598 | $18,151.91 | 7,306 | 2025-12-03 | Filing | |
| $5.04 | 3,521 | $17,747.95 | 9,785 | 2025-12-03 | Filing | |
| $5.00 | 2,556 | $12,787.67 | 6,264 | 2025-12-03 | Filing | |
| $4.87 | 3,708 | $18,052.77 | 3,708 | 2025-12-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.60 | 200 | $1,320.00 | 105,111 | 2016-07-08 | Filing | |
| $6.59 | 394 | $2,596.46 | 105,311 | 2016-07-08 | Filing | |
| $6.55 | 500 | $3,275.00 | 105,705 | 2016-07-08 | Filing | |
| $6.51 | 100 | $651.00 | 106,205 | 2016-07-08 | Filing | |
| $6.50 | 400 | $2,600.00 | 106,305 | 2016-07-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 260,327 | $1,647,870 | 0% | |
| 2. | 221,716 | $1,403,462 | 0% | |
| 3. | 135,267 | $856,240 | 0% | |
| 4. | 101,594 | $643,090 | 0.11% | |
| 5. | 65,765 | $416,393 | 0% |
News See All
Here's Why ImmuCell Corporation (ICCC) is Emerging as an Intriguing Micro-Cap Opportunity
Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund" Q1 2026 Investor Letter. A copy of the letter can be downloaded here.
ImmuCell Corporation (NASDAQ:ICCC) Q4 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the ImmuCell Corporation Conference Call to discuss Unaudited Fourth Quarter and Full Year 2025 Financial Results.
ImmuCell Corporation (NASDAQ:ICCC) Q3 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the ImmuCell Corporation Reports Third Quarter ended September 30, 2025, Unaudited Financial Results Conference Call.
ImmuCell Corporation (NASDAQ:ICCC) Q2 2025 Earnings Call Transcript
Operator: Good morning, and welcome to ImmuCell Corporation Reports Second Quarter Ended June 30, 2025 Unaudited Financial Results Conference Call.
ImmuCell Corporation (NASDAQ:ICCC) Q1 2025 Earnings Call Transcript
Operator: Good morning and welcome to the ImmuCell Corporation Reports First Quarter Ended March 31st, 2025 Audited Financial Results Conference Call. All participants will be in listen-only mode.
ImmuCell Corporation (NASDAQ:ICCC) Q4 2024 Earnings Call Transcript
Operator: Good morning, and welcome to ImmuCell Corporation Reports its Fourth Quarter and Year Ended December 31, 2024, Unaudited Financial Results Conference Call.
ImmuCell Corporation (NASDAQ:ICCC) Q3 2024 Earnings Call Transcript
Operator: Good morning and welcome to ImmuCell Corporation Reports Third Quarter September 30, 2024, Unaudited Financial Results Conference Call. All participants will be in listen-only mode.
ImmuCell Corporation (NASDAQ:ICCC) Q2 2024 Earnings Call Transcript
Operator: Good morning, and welcome to the ImmuCell Corporation Reports Second Quarter ended June 30, 2024, Unaudited Financial Results Conference Call. All participants will be in a listen-only mode.
ImmuCell Corporation (NASDAQ:ICCC) Q1 2024 Earnings Call Transcript
Operator: Good morning, and welcome to the ImmuCell Corporation Reports First Quarter ended March 31, 2024 Unaudited Financial Results Conference Call. All participants are in a listen-only mode.